CANreduce 3.0 - a web-based self-help program for reducing cannabis use that explores the effectiveness of mindfulness and cognitive behavioral therapy approaches

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
09/09/2021		[X] Protocol		
Registration date	Overall study status Completed Condition category	Statistical analysis plan		
09/09/2021		Results		
Last Edited		Individual participant data		
06/12/2022	Mental and Behavioural Disorders	Record updated in last year		

Plain English summary of protocol

Background and study aims

In European countries, including Switzerland, as well as in many states worldwide, cannabis is the most widely used psychoactive substance (a chemical known to change brain function) after alcohol and tobacco. Although approximately one in ten users develop serious problems of dependency, only a small number attend outpatient addiction counseling centers. The offer of a web-based self-help program could potentially also reach those users who hesitate to approach such treatment centers and help them to reduce their cannabis use.

This study will test the effectiveness of two versions of a web-based self-help intervention (program) in reducing cannabis use in problematic users. One version is based on classical therapy (cognitive behavioral therapy) and one is based on mindfulness. A third condition is a waiting list control group.

Who can participate?

Adults (aged 18 years or above) who can read and write in German and have used cannabis at least once a week during the last 30 days.

What does the study involve?

Participants are randomly allocated to one of three groups. The two intervention groups consist of a 6-week, web-based self-help program (CANreduce) with a consumption diary, eight modules designed to help people to reduce their cannabis intake based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioural therapy (arm 1) or a mindfulness-based therapy (arm 2). The waiting control group are placed on a waiting list; after 6 months they can start the program, too. All participants are followed up after 6 weeks, 3 and 6 months to see whether they have reduced their cannabis use.

What are the possible benefits and risks of participating?

A possible benefit to participation is using less cannabis. Possible risks include experiencing mild cravings and depression.

Where is the study run from?
Swiss Research Institute for Public Health and Addiction (ISGF) (Switzerland)

When is the study starting and how long is it expected to run for? April 2020 to March 2024

Who is funding the study?
Swiss National Science Foundation

Who is the main contact?

Prof. Dr Michael Schaub, michael.schaub@isgf.uzh.ch

Contact information

Type(s)

Scientific

Contact name

Prof Michael Schaub

ORCID ID

https://orcid.org/0000-0002-8375-4005

Contact details

Konradstrasse 32 Zürich Switzerland 8005 +41 44 448 11 65 michael.schaub@isgf.uzh.ch

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

20.4.17, 10001C_192301 / 1

Study information

Scientific Title

CANreduce 3.0 - Randomized controlled trial testing the effectiveness of two different versions (mindfulness and CBT) of an adherence-focused web-based self-help intervention to reduce cannabis use in frequent cannabis users

Acronym

CANreduce 3.0

Study objectives

Current study hypothesis as of 24/01/2022:

- 1. A web-based self-help program with focus on mindfulness (arm 1) is more effective than the waiting list control condition (study arm 3) in reducing cannabis use in frequent cannabis users
- 2. A web-based self-help program with focus on cognitive behavioral therapy (arm 2) is more effective than the waiting list control condition (study arm 3) in reducing cannabis use in frequent cannabis users
- 3. A web-based self-help program with focus on mindfulness (arm 1) is at least as effective as one with focus on cognitive behavioral therapy (arm 2) in frequent cannabis users.

Previous study hypothesis:

- 1. A web-based self-help program with focus on mindfulness (arm 1) is more effective than the waiting list control condition (study arm 3) in reducing cannabis use in cannabis misusers
- 2. A web-based self-help program with focus on cognitive behavioral therapy (arm 2) is more effective than the waiting list control condition (study arm 3) in reducing cannabis use in cannabis misusers
- 3. A web-based self-help program with focus on mindfulness (arm 1) is similarly effective as one with focus on cognitive behavioral therapy (arm 2) in cannabis misusers.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 22/04/2020, Ethics Committee, Faculty of Arts and Social Science, University Zurich (Institute of Psychology, Binzmühlestrasse 14, Box 22, 8050 Zurich, Switzerland; +41 (0)44 635 74 70; k.oberauer@psychologie.uzh.ch), ref: 20.4.17

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Frequent cannabis use

Interventions

Current interventions as of 24/01/2022:

The three-arm randomized controlled trial aims to test the effectiveness of a newly developed integrated mindfulness-based minimally guided self-help Internet intervention (Arm 1) and a cognitive-behavioral minimally guided self-help Internet intervention (reference product; Arm 2) with a control condition (Arm 3) in 630 individuals with frequent cannabis use. Moreover, we will explore similarities between the main intervention (arm 1) and the reference product (arm 2) for the effect size of the difference between the two study arms with confidence interval approaches including a priori set equivalence margin. In addition, the project intends to identify

and compare relevant predictors of retention, adherence, and treatment outcomes for the two main intervention arms. The primary outcome is the number of days of cannabis use in the last 30 days.

Participants are randomly allocated to one of three arms:

- 1. Intervention 1: Web-based self-help program with focus on mindfulness
- 2. Intervention 2: Web-based self-help program with focus on cognitive behavioral therapy
- 3. Control group: Waiting list

CANreduce is an automated web-based self-help tool based on classical CBT approaches (expanded with mindfulness for this trial) for treating adults with frequent cannabis use. It will take 6 weeks and consists of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive-behavioural therapy (strategies for goal achievement, identifying risk situations, dealing with cannabis craving, dealing with relapses, working on needs, saying "no" to foster refusal skills, dealing with burdens, preserving achievements).

The control condition is a waiting list. After 6 months they will be given the opportunity to start the self-help program (study arm 1).

The masking technique will be single-blind, insofar that participants are only informed that "two different interventions" are being studied but not that they are mindfulness and CBT based. However, they will know if they have been assigned to the waiting list.

Once participants have completed their baseline assessment, they will be randomly assigned by a software-generated random number to one of the three groups.

Previous interventions:

The three-arm randomized controlled trial aims to test the superiority of a newly developed integrated mindfulness-based minimally guided self-help Internet intervention (Arm 1) and a cognitive-behavioral minimally guided self-help Internet intervention (reference product; Arm 2) with a control condition (Arm 3) in 630 individuals who abuse cannabis. Moreover, we will explore similarities between the main intervention (arm 1) and the reference product (arm 2) for the effect size of the difference between the two study arms with confidence interval approaches including a priori set equivalence margin. In addition, the project intends to identify and compare relevant predictors of retention, adherence, and treatment outcomes for the two main intervention arms. The primary outcome is the number of days of cannabis use in the last 30 days.

Participants are randomly allocated to one of three arms:

- 1. Intervention 1: Web-based self-help program with focus on mindfulness
- 2. Intervention 2: Web-based self-help program with focus on cognitive behavioral therapy
- 3. Control group: Waiting list

CANreduce is an automated web-based self-help tool based on classical CBT approaches for treating cannabis dependence. It will take 6 weeks and consists of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioural therapy (strategies for goal achievement, identifying risk situations, dealing with cannabis craving, dealing with relapses, working on needs, saying "no" to foster refusal skills, dealing with burdens, preserving achievements).

The control condition is a waiting list. After 6 months they will be given the opportunity to start the self-help program.

The masking technique will be single-blind, insofar that participants are only informed that "two different interventions" are being studied but not that they are mindfulness and CBT based. However, they will know if they have been assigned to the waiting list.

Once participants have completed their baseline assessment, they will be randomly assigned by a software generated random number to one of the three groups.

Intervention Type

Behavioural

Primary outcome(s)

Number of days of cannabis use in the last 30 days measured using self-report at baseline, after 6 weeks, and at 3 and 6 months follow-up.

Key secondary outcome(s))

Current secondary outcome measures as of 24/01/2022:

- 1. Cannabis use frequency and amount over the past 7 days according to the "time-line-follow-back" (TLFB) method
- 2. Consumption patterns (years of cannabis use, 30-day point prevalence of cannabis and CBD use, type of consumption)
- 3. Cannabis use (CUDIT-R)
- 4. Alcohol abuse (AUDIT-C)
- 5. Perceived Stress (PSS-10)
- 6. Comprehensive Inventory of Mindfulness Experience (CHIME)
- 7. Depression (PHQ-9)
- 8. Generalized Anxiety (GAD-7)
- 9. Client Satisfaction
- 10. Negative effects according to Rozental et al. (2016)
- 11. Mindfulness Attention Awareness Scale (MAAS)
- 12. Severity of Dependence Scale (SDS)
- 13. National Institute on Drug Abuse Screening (NIDA-ASSIST)
- 14. Drug Abuse Screening Test (DAST-10)
- 15. Adult ADHD Self-Report Scale (ASRS-V1.1)

Some measures are taken at baseline (all but 9 and 10), some after 6 weeks (1, 2, 3, 5, 9, 10, 11, 12) and some after 3 and 6 months follow-up (1, 2, 3, 4, 5, 7, 8, 11, 12, 13)

Previous secondary outcome measures:

At baseline, after 6 weeks, and at 3 and 6 months follow-up.

- 1. Cannabis use frequency and amount over the past 7 days according to the "time-line-follow-back" (TLFB) method.
- 2. Number of days of CBD use in the last 30 days
- 3. Cannabis use (CUDIT)
- 4. Alcohol abuse (AUDIT-C)
- 5. Perceived Stress (PSS-10)
- 6. Comprehensive Inventory of Mindfulness Experience (CHIME)
- 7. Depression (PHQ-9)

- 8. Generalized Anxiety (GAD-7)
- 9. Client Satisfaction
- 10. Adverse effects according to Rozental et al. (2016)

Completion date

31/03/2024

Eligibility

Key inclusion criteria

Current inclusion criteria as of 24/01/2022:

- 1. Cannabis use of at least once a week 30 days prior to study entry
- 2. At least 18 years old
- 3. At least weekly internet access and a valid email address and phone number
- 4. Informed consent (via a web form)

Previous inclusion criteria:

- 1. Cannabis use of at least once a week 30 days prior to study entry
- 2. At least 18 years old
- 3. At least weekly internet access and a valid email address

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

- 1. Current pharmacological psychiatric disease or history of psychosis, schizophrenia, bipolar type I disorder or significant current suicidal thoughts
- 2. Use of other pharmacological and psycho-social treatments for cannabis use disorders
- 3. Inability to read or write in German

Date of first enrolment

13/09/2021

Date of final enrolment

13/09/2023

Locations

Countries of recruitment

Austria

Germany

Switzerland

Study participating centre Swiss Research Institute for Public Health and Addiction (ISGF)

Konradstrasse 32 Zürich Switzerland 8005

Sponsor information

Organisation

University of Zurich

ROR

https://ror.org/02crff812

Funder(s)

Funder type

Government

Funder Name

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Alternative Name(s)

Schweizerischer Nationalfonds, Swiss National Science Foundation, Fonds National Suisse de la Recherche Scientifique, Fondo Nazionale Svizzero per la Ricerca Scientifica, Fonds National Suisse, Fondo Nazionale Svizzero, Schweizerische Nationalfonds, The Swiss National Science Foundation (SNSF), SNF, SNSF, FNS

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Switzerland

Results and Publications

Individual participant data (IPD) sharing plan

Fully anonymized data will be shared with qualified and trusted individuals for further use upon request (for example, for individual-patient data metanalyses). michael.schaub@isgf.uzh.ch

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		24/03/2022	06/12/2022	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes